Gardasil approved to prevent anal cancer

The FDA has approved Gardasil (human papillomavirus quadrivalent [types 6, 11, 16, and 18] vaccine, recombinant, from Merck) for the prevention of anal cancer caused by human papillomavirus (HPV) types 16 and 18 and for the prevention of anal intraepithelial neoplasia (AIN) grades 1, 2 and 3 (anal dysplasias and precancerous lesions) caused by HPV types 6, 11, 16 and 18 in males and females ages 9—26 years.

Gardasil is already indicated in females 9–26 years old, to prevent cervical, vulvar, and vaginal cancer caused by HPV types 16 and 18; genital warts caused by HPV types 6 and 11; cervical adenocarcinoma in situ (AIS) and cervical intraepithelial neoplasia (CIN) grades 2 and 3, vulvar intraepithelial neoplasia (VIN) grades 2 and 3, vaginal intraepithelial neoplasia (VaIN) grades 2 and 3, and cervical intraepithelial neoplasia (CIN) grade 1 caused by HPV types 6, 11, 16, and 18. Gardasil is also indicated in males 9—26 years old, to prevent genital warts caused by HPV types 6 and 11.

For more information call (800) 672-6372 or visit www.gardasil.com.